SOLID TUMOURS

This early-phase study tests the safety of a new drug called AP601 in 36 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find the highest dose that can be given safely. Participants receive one of six dose levels, and the stud…

This early-stage study tests a new drug called BMS-986517 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goal is to check the drug's safety and side effects. About 315 participants will receive the drug, and researchers will also l…

This early-stage study tests a new drug called BI 3810944 in adults with advanced solid tumors or melanoma who have run out of treatment options. The goal is to find safe doses and see if the drug can shrink tumors. Participants receive the drug every three weeks, with more frequ…

This early-stage study is testing a new under-the-skin injection of the cancer drug durvalumab for adults with solid tumours. The goal is to find a dose that works as well as the standard IV version. About 40 participants will be enrolled to check safety and how the drug moves th…

This study tests an experimental drug called AZD4956, alone or with other cancer treatments, in people with advanced or spreading solid tumors that have a specific DNA repair flaw. About 180 adults will take part to see if the drug is safe and works. The goal is to control the di…

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB), high microsatellite instability (MSI), or a specific DNA repair defect (CMMRD). About 30 adults, teens, and children will receive the…

This study tests a daily oral drug called zongertinib for adults with advanced solid tumors that have HER2 mutations or overexpression. Participants must have already tried other treatments without success. The goal is to see if zongertinib can shrink tumors and control the disea…

This early-stage study tests a new drug called RC220 given together with a standard chemotherapy (doxorubicin) in adults with advanced solid tumours. The main goals are to find the safest dose and see if RC220 can protect the heart from doxorubicin's side effects. About 53 people…

This study tests a new drug called ODM-212 in people with advanced solid tumours that cannot be cured with standard treatments. The trial has two parts: first finding a safe dose, then testing that dose in more patients. Researchers will monitor side effects and how the tumours r…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study aims to collect tumor and blood samples from 3000 adults with solid tumors to learn why cancers become resistant to treatments and spread. Researchers will use advanced lab tests to find molecular clues. The goal is to develop better treatments and tests for individual…

This study is a large registry that will collect information from 15,000 adults with solid tumors who have had a genetic test called next-generation sequencing. The goal is to understand how these test results relate to the treatments patients receive and their overall survival. …